Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Myriad Genetics, Inc. - Common Stock
(NQ:
MYGN
)
4.070
-0.380 (-8.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Myriad Genetics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
November 03, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
November 02, 2022
Gainers
Via
Benzinga
Myriad Genetics Q3 Earnings Fall Short Of Expectations, Lowers Annual Outlook
November 01, 2022
Via
Benzinga
Nasdaq Down 60 Points; Eli Lilly Lowers Earnings Forecast
November 01, 2022
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 70 points on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 01, 2022
Gainers
Via
Benzinga
Dow Drops Over 200 Points; Crude Oil Rises Sharply
November 01, 2022
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 200 points on Tuesday.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
November 01, 2022
On Tuesday, 85 stocks hit new 52-week lows.
Via
Benzinga
Analyst Initiates Coverage On This Genetic Testing Stock With Ongoing Transformation
October 06, 2022
Via
Benzinga
Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session
November 01, 2022
Gainers Safe-T Group Ltd (NASDAQ: SFET) shares surged 63.7% to $0.4910 as the company said its privacy application reached over 5,000,000 downloads.
Via
Benzinga
Goodyear Tire, Catalent, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday
November 01, 2022
U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Recap: Myriad Genetics Q1 Earnings
May 05, 2022
Myriad Genetics (NASDAQ:MYGN) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:05 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Myriad Genetics: Q3 Earnings Insights
November 01, 2022
Myriad Genetics (NASDAQ:MYGN) reported its Q3 earnings results on Tuesday, November 1, 2022 at 09:05 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test
November 01, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Reports Third Quarter Financial Results
November 01, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member
October 31, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Earnings Scheduled For November 1, 2022
November 01, 2022
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.
Via
Benzinga
Earnings Preview: Myriad Genetics
October 31, 2022
Myriad Genetics (NASDAQ:MYGN) is set to give its latest quarterly earnings report on Tuesday, 2022-11-01. Here's what investors need to know before the announcement. Analysts estimate that Myriad...
Via
Benzinga
Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022
October 26, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Precision Medicine Could Get Even More Precise With Allarity Therapeutics' "Next-Generation" Diagnostics Platform
October 17, 2022
Allarity Therapeutics Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on oncology treatments.
Via
Benzinga
Is Illumina Still the Gamechanger in Genomics Sequencing?
October 04, 2022
Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused
Via
MarketBeat
Topics
Earnings
Economy
Lawsuit
Exposures
Financial
Legal
Supply Chain
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022
October 06, 2022
Upgrades
Via
Benzinga
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds
September 28, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022
July 28, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Can Artificial Intelligence Predict Our Future Health?
July 05, 2022
Thousands of financial investors and Wall Street pundits advise people daily about what economic trends are coming, what stocks are hot and what is on the upswing. Those same investors and banks...
Via
Benzinga
40 Stocks Moving In Tuesday's Mid-Day Session
May 31, 2022
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares jumped 360.8% to $9.86 after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
June 01, 2022
On Wednesday, 73 stocks hit new 52-week lows.
Via
Benzinga
Myriad Genetics's Earnings: A Preview
May 04, 2022
Myriad Genetics (NASDAQ:MYGN) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Myriad...
Via
Benzinga
77 Biggest Movers From Yesterday
June 01, 2022
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate...
Via
Benzinga
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
April 20, 2022
The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was...
Via
Benzinga
AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer
March 14, 2022
The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) cancer drug, jointly developed with Merck & Co Inc (NYSE: MRK) to treat patients with early-...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.